Purchase this article with an account.
Ermengarda Marziani, Simone Pomati, Paola Ramolfo, Mario Cigada, Andrea Giani, Claudio Mariani, Giovanni Staurenghi; Retinal Nerve Fibre Layer And Ganglion Cells Layer Thickness Evaluation In Alzheimer Disease: Follow-Up Study. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3672.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To follow-up differences in variation of Retinal Nerve Fibre Layer (RNFL) thickness and RFNL+ Ganglion Cells Layer (GCL) between patients affected by Alzheimer Disease (AD) and age-matched healthy patients
Exclusion criterion was the presence of any possible cause of RNFL and GCL alteration. Patients and controls underwent neurological examination, clock drawing test (CDT), Mini Mental State Examination (MMSE) and comprehensive ophthalmic evaluation at six months and one year follow-up. Spectral-Domain Optical Coherence Tomography (SD-OCT) examination was performed using Spectralis SD-OCT(Heidelberg Engineering,Heidelberg,Germany), and RTVue-100 (Optovue Inc., Freemont, CA, USA). RNFL thickness map was obtained using Spectralis volume protocol with 19 lines on 30° field centred on optic disk. On each B-scan the outer RNFL limit was manually delineated. RFNL+GCL thickness map was obtained using RTVue-100 MM6 protocol. Maps were divided in 9 zones (central, superior internal, temporal internal, inferior internal, nasal internal, superior external, temporal external, inferior external, nasal external) and each map value in every field was evaluated
We analyzed 23 AD patients: (23 eyes) and 29 controls at baseline; 18 AD patients (18 eyes) and 24 controls (24 eyes) at six months; and 14 AD patients (14 eyes) and 21 controls (21 eyes) at one year. A significant difference between RNFL and RNFL+GCL thickness in AD patients and controls was found in all the fields (p between <0.001 and 0.026 for RTVue-100; p between <0.001 and 0.002 for Spectralis) at each of the studied time points. A significant RNFL reduction through the time points was demonstrated in both AD patients and controls when using Spectralis (p between <0.001 and 0.003); no significant reduction of RNFL+GCL through the time points was demonstrated in AD patients and controls (p between 0.2 and 0.87).
RFNL thickness measurements decreased through the time points, while RNFL+GCL thickness remained stable. Further studies are necessary to assess the use of SD-OCTs in the evaluation of disease progression.
This PDF is available to Subscribers Only